Share on StockTwits
 

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) major shareholder Francis Reynolds sold 25,000 shares of the stock on the open market in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $2.25, for a total value of $56,250.00. Following the completion of the sale, the insider now directly owns 9,861,420 shares of the company’s stock, valued at approximately $22,188,195. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Separately, analysts at Aegis cut their price target on shares of Invivo Therapeutics Holdings Corp from $7.00 to $4.00 in a research note on Monday, November 25th. They now have a “buy” rating on the stock.

Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded down 0.88% on Wednesday, hitting $2.24. 106,921 shares of the company’s stock traded hands. Invivo Therapeutics Holdings Corp has a 52-week low of $0.94 and a 52-week high of $6.20. The stock has a 50-day moving average of $2.28 and a 200-day moving average of $2.05. The company’s market cap is $176.4 million.

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.